• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

B4GalT1 – A Druggable Target for the Treatment of Glioblastoma

by Bellbrook Labs / Tuesday, 21 September 2021 / Published in Emerging Targets, HTS Assays
B4GalT1 A Target to Stop Glioblastoma

Multi-faceted Properties of B4GalT1

Beta-1,4-Galactosyltransferase 1 (B4GalT1) belongs to the galactosyltransferase (GalT) family of enzymes that transfer galactose from uridine-diphosphate-α-D-galactose (UDP-Gal) to an acceptor sugar molecule. B4GalT1 is a critical enzyme in galactose metabolism.

One of the first GalT to be characterized biochemically, B4GalT1, was also involved in lactose production by interacting with α-lactalbumin during lactation1. However, more evidence has surfaced over the years illustrating B4GalT1’s role in other physiological processes such as aging2.

 

The Intimate Relationship Between B4GalT1 and Human Cancers

Several new studies have linked B4GalT1 expression to some forms of cancer. B4GalT1 was recently found to be involved in the proliferation and maintenance of cancer stem cells of lung adenocarcinoma3. Another study reported that high B4GalT1 expression in bladder cancer patients was also observed to correlate with low overall survival and expression of inhibitory receptor signals PD-1 and CTLA4. The effectiveness of adjuvant chemotherapy was also found to be higher in bladder cancer patients with lower expression levels of B4GalT14. Elevated B4GalT1 levels were also seen in megakaryocytes from myeloproliferative neoplasms5. Therefore B4GalT1 seems to play an essential role in human cancers, although more work has to be done to thoroughly examine the underlying mechanisms contributing to this relationship.

Targeting B4GalT1 for the Treatment of Glioblastoma

Glioblastoma multiforme (GBM), also known as glioblastoma, is the most aggressive and common form of glioma (a tumor that occurs in the brain and spine)6. Glioblastoma is a fast-growing, grade 4 glioma. Most patients with glioblastoma typically do not survive for more than a year. Due to the tumor’s complexity, glioblastoma remains an incurable disease, and treatment options are still relatively limited.

The involvement of B4GalT1 in glioblastoma is relatively unknown. However, a group of researchers reported for the first time that B4GalT1 expression was elevated in glioblastoma tumor tissue and human primary glioblastoma cells (U87)7. By reducing the expression of B4GalT1 in vitro, the proliferative and migratory capacity of U87 cells was suppressed. Mice injected with U87 cells expressing lower levels of B4GalT1 developed significantly smaller tumors and had a better survival rate than mice injected with normal U87 cells. They also discovered that underlying this phenomenon was that lower B4GalT1 expression induces apoptosis and autophagy of glioblastoma both in vitro and in vivo, therefore promoting cancer cell death. Hence, B4GalT1 plays critical role in regulating glioblastoma development. Targeting B4GalT1 for the treatment of glioblastoma is a highly viable approach that has to be further validated.

BellBrook’s Transcreener UDP2 Assay is a universal UDP detection HTS assay that utilizes a fluorescence-based method to measure glycosyltransferase activity by detecting UDP production.

How the Transcreener UDP2 Assay can facilitate B4GalT1 research:

  • Evaluate enzymatic activity
  • Screen for small molecule inhibitors
  • Determine inhibitor potency/ IC50 values
  • Profile inhibitor selectivity
  • Support mechanistic studies

References

  1. Qasba, P. K., Ramakrishnan, B. & Boeggeman, E. Structure and Function of β-1,4-Galactosyltransferase. Curr Drug Targets 9, 292–309 (2008).
  2. Kremer, J., Brendel, C., Mack, E. K. M. & Mack, H. I. D. Expression of β-1,4-galactosyltransferases during Aging in Caenorhabditis elegans. GER 66, 571–581 (2020).
  3. De Vitis, C. et al. B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells. Journal of Clinical Medicine 8, 1928 (2019).
  4. Xie, H. et al. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients. BMC Cancer 18, 590 (2018).
  5. Di Buduo, C. A. et al. Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs. Blood 137, 2085–2089 (2021).
  6. Holland, E. C. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci U S A 97, 6242–6244 (2000).
  7. Wang, P., Li, X. & Xie, Y. B4GalT1 Regulates Apoptosis and Autophagy of Glioblastoma In Vitro and In Vivo. Technol Cancer Res Treat 19, 1533033820980104 (2020).
Tagged under: B4GalT1 Assay, Glioblastoma Research, Transcreener UDP Assay

What you can read next

Webinar: Streamline HTS and Lead Discovery with the Transcreener ADP Kinase Assay
ADP Detection: It’s not all about kinases
New Posters from DOT 2017

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP